OTCMKTS:ALPMY Astellas Pharma Q1 2026 Earnings Results & Report $14.39 +0.04 (+0.28%) As of 03:59 PM Eastern Astellas Pharma beat analyst expectations on both earnings and revenue in its Q1 2026 results, released July 30, 2025. The company reported EPS of $0.40 versus the $0.1356 consensus estimate, while revenue of $3.41 billion topped the $3.20 billion estimate by $204.95 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateJuly 30, 2025TimeBefore Market Opens Astellas Pharma EPS ResultsActual EPS$0.40Consensus EPS $0.1356Beat/MissBeat by +$0.2644One Year Ago EPSN/AEPS Beat Rate5 of last 7 quartersAstellas Pharma Revenue ResultsActual Revenue$3.41 billionExpected Revenue$3.20 billionBeat/MissBeat by +$204.95 millionYoY Revenue GrowthN/AUpcoming EarningsAstellas Pharma's next earnings date is estimated for Wednesday, November 4, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Astellas Pharma Q1 2026 Earnings FAQ Did Astellas Pharma beat earnings estimates for Q1 2026? Astellas Pharma (OTCMKTS:ALPMY) reported earnings of $0.40 per share for Q1 2026, beating the consensus estimate of $0.1356. The report was announced on Wednesday, July 30, 2025. What was Astellas Pharma's revenue for Q1 2026? Astellas Pharma reported revenue of $3.41 billion for Q1 2026, against a consensus estimate of $3.20 billion. When is Astellas Pharma's next earnings date? Astellas Pharma's next earnings date is estimated for Wednesday, November 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Astellas Pharma on the company's earnings history page. Astellas Pharma Earnings HeadlinesAstellas Pharma (OTCMKTS:ALPMY) Shares Gap Down - Here's What HappenedOctober 12 at 11:21 AM | americanbankingnews.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Stock Short Interest Rises 519.9%October 10 at 3:01 AM | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Head-To-Head Contrast: Heron Therapeutics (NASDAQ:HRTX) vs. Astellas Pharma (OTCMKTS:ALPMY)October 9, 2026 | americanbankingnews.comAstellas Pharma (OTCMKTS:ALPMY) Shares Gap Up - Here's WhyOctober 3, 2026 | americanbankingnews.comMizuho Securities Sticks to Their Hold Rating for Astellas Pharma (ALPMF)September 15, 2026 | theglobeandmail.comSee More Astellas Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Astellas Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astellas Pharma and other key companies, straight to your email. Email Address About Astellas PharmaAstellas Pharma (OTCMKTS:ALPMY) is a Japan-based pharmaceutical company that researches, develops, manufactures and commercializes prescription medicines for patients worldwide. Its portfolio focuses on areas of significant unmet medical need, including oncology, immunology, urology, ophthalmology, neuroscience and medical conditions related to genetic regulation. The company’s products include XTANDI (enzalutamide) for certain prostate cancers, XOSPATA (gilteritinib) for acute myeloid leukemia, PADCEV (enfortumab vedotin-ejfv) for certain urothelial cancers, and PROGRAF (tacrolimus), an immunosuppressant used primarily to help prevent organ rejection following transplantation. Astellas also develops medicines and investigational therapies through internal research and collaborations with biotechnology and pharmaceutical companies. Astellas was established in 2005 through the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., two Japanese companies with histories dating back several decades. Headquartered in Tokyo, the company serves markets across North America, Europe, Asia and other regions through a global research, development and commercial organization. Naoki Okamura serves as Astellas Pharma’s president and chief executive officer.View Astellas Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
